120
Participants
Start Date
April 29, 2024
Primary Completion Date
May 1, 2026
Study Completion Date
November 1, 2026
The Accelerate model of care
"Contact is established by the study team~The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact~At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study~The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.~B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.~A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.~Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider."
bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
Same as above, it is the same intervetion
RECRUITING
NOVUS Health, St Louis
RECRUITING
KC Care Health Center, Kansas City
RECRUITING
University of Missouri-Columbia, Columbia
RECRUITING
AIDS Project of the Ozarks, Springfield
Collaborators (1)
Gilead Sciences
INDUSTRY
University of Missouri-Columbia
OTHER